Aging is accompanied by progressive changes in cellular structure and function that reduce the ability of tissues to maintain homeostasis and respond effectively to stress. Among the biological processes associated with aging, cellular senescence has emerged as an important mechanism linking accumulated cellular damage with tissue dysfunction and age-related disease.

Cellular senescence is generally characterized by a stable arrest of cell proliferation in response to different endogenous and exogenous stresses. These include telomere shortening, persistent DNA damage, oxidative stress, oncogene activation, mitochondrial dysfunction, and metabolic disturbances. Senescence can serve as a protective response by preventing damaged cells from continuing to divide and potentially becoming malignant. At the same time, persistent accumulation of senescent cells can contribute to pathological inflammation and tissue deterioration.

The biological effects of senescence are therefore context dependent. During embryogenesis, wound healing, and tissue remodeling, senescent cells can contribute to normal development and repair. In contrast, prolonged persistence of senescent cells during aging can promote chronic inflammation and impaired tissue function.

One of the most important features of senescent cells is the senescence-associated secretory phenotype (SASP). SASP includes inflammatory cytokines, chemokines, growth factors, extracellular matrix-modifying enzymes, and other signaling molecules. These factors can influence neighboring cells and potentially extend the effects of senescence beyond the original cell population.

The accumulation of senescent cells has been associated with numerous age-related disorders. Evidence implicates cellular senescence in cardiovascular disease, metabolic disorders, neurodegeneration, osteoporosis, pulmonary disease, liver disease, and cancer.

Recent advances have also led to the development of senotherapies. Senolytic approaches aim to selectively eliminate senescent cells, whereas senomorphic approaches attempt to suppress harmful SASP activity. Other strategies seek to modify the molecular pathways that initiate or maintain senescence.

The purpose of this review is to examine the molecular mechanisms underlying cellular senescence and to discuss its implications for aging and age-related human diseases, with particular emphasis on emerging therapeutic opportunities.

2. Cellular Senescence: Biological Concept

Cellular senescence was initially recognized through observations that normal human cells have a limited capacity for replication in culture. Subsequent research established that senescence is not simply the result of exhaustion but can be actively induced by different forms of cellular stress.

Senescent cells remain metabolically active but display a stable reduction or cessation of cell-cycle progression. They frequently exhibit enlarged and flattened morphology, increased lysosomal content, altered metabolism, persistent DNA damage signaling, and changes in chromatin organization.

Senescence should be distinguished from quiescence. Quiescent cells are metabolically less active and can generally re-enter the cell cycle when appropriate growth signals become available. Senescent cells, in contrast, display persistent cell-cycle arrest associated with broader molecular and functional changes.

Importantly, senescence is heterogeneous. Different stimuli and cell types can generate distinct senescent phenotypes. Consequently, no single molecular marker is currently sufficient to identify all senescent cells under every biological condition.

3. Major Inducers of Cellular Senescence

Telomere Shortening

Telomeres are specialized DNA-protein structures located at chromosome ends. With repeated cell division, telomeres progressively shorten in many somatic cells.

When telomeres become critically short or dysfunctional, chromosome ends can be recognized as DNA damage. This activates DNA damage response pathways and can ultimately induce permanent cell-cycle arrest.

Telomere dysfunction is therefore an important mechanism linking replicative history with cellular senescence and aging.

DNA Damage

DNA damage is one of the most powerful triggers of cellular senescence. Sources include ionizing radiation, ultraviolet radiation, replication stress, oxidative damage, environmental toxins, and endogenous metabolic processes.

Persistent DNA damage activates the DNA damage response, involving sensor and signaling proteins such as ATM, ATR, CHK1, and CHK2. These pathways can activate p53 and subsequently increase expression of cell-cycle inhibitors.

Persistent DNA damage signaling has been strongly linked to senescence-associated inflammation and age-related disease.

Oxidative Stress

Reactive oxygen species can damage DNA, proteins, lipids, and cellular organelles. Persistent oxidative stress can activate signaling pathways that promote cellular senescence.

Mitochondria are particularly important because they are both sources and targets of reactive oxygen species. Mitochondrial dysfunction can increase oxidative stress and promote additional cellular damage, potentially reinforcing the senescent phenotype.

Oncogene Activation

Aberrant activation of oncogenes can induce a protective form of senescence known as oncogene-induced senescence.

This mechanism can prevent cells with potentially dangerous proliferative signals from undergoing uncontrolled division. However, the secretory phenotype associated with senescent cells may have complex effects on surrounding tissues and tumors.

Metabolic Stress

Changes in glucose availability, lipid metabolism, mitochondrial function, nutrient sensing, and energy balance can influence senescence.

Senescent cells frequently undergo substantial metabolic reprogramming, and metabolic alterations can both promote senescence and be consequences of the senescent state.

4. Molecular Pathways of Cellular Senescence

The p53–p21 Pathway

The tumor suppressor protein p53 is a major regulator of cellular responses to DNA damage and cellular stress.

Following persistent DNA damage, p53 can become activated and stimulate transcription of p21, encoded by the CDKN1A gene. Increased p21 inhibits cyclin-dependent kinases and prevents progression through the cell cycle.

Persistent activation of the p53–p21 pathway therefore contributes to stable cell-cycle arrest.

The p16–Retinoblastoma Pathway

The p16 protein, encoded by CDKN2A, is another major regulator of senescence.

p16 inhibits cyclin-dependent kinases such as CDK4 and CDK6, thereby maintaining the retinoblastoma protein in an active state. This suppresses E2F-dependent transcription and prevents cell-cycle progression.

The p16–RB pathway is particularly important in maintaining stable senescence once the phenotype has developed. Current evidence indicates that p16/CDKN2A and p21/CDKN1A are among the most commonly investigated senescence-associated markers, although neither is universally specific for senescence.

DNA Damage Response

Persistent DNA damage activates a complex network of signaling pathways that communicate between damaged DNA, cell-cycle regulators, chromatin, and inflammatory pathways.

Long-lasting DNA damage can maintain senescence even after the original damaging stimulus has disappeared.

The interaction between DNA damage response and senescence is particularly relevant to aging because accumulated DNA damage increases throughout life and may contribute to chronic inflammatory signaling.

NF-κB and Inflammatory Signaling

NF-κB is an important regulator of inflammatory gene expression and plays a central role in SASP development.

Activation of NF-κB promotes production of inflammatory cytokines and chemokines, including interleukin-6 and interleukin-8.

Persistent inflammatory signaling can establish a feedback mechanism in which SASP factors stimulate inflammation in neighboring cells, potentially promoting additional senescence.

p38 MAPK Signaling

The p38 mitogen-activated protein kinase pathway responds to cellular stress and contributes to senescence-associated signaling.

Persistent activation of p38 can influence cell-cycle arrest, inflammatory signaling, and SASP production.

mTOR Signaling

The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, metabolism, protein synthesis, and nutrient sensing.

Changes in mTOR activity can influence the development and maintenance of senescence. Because mTOR also regulates cellular metabolism and autophagy, it represents an important link between nutrient sensing, aging, and cellular senescence.

5. Senescence-Associated Secretory Phenotype

The SASP represents one of the most biologically significant features of many senescent cells.

SASP components can include:

• Interleukin-6
• Interleukin-8
• Tumor necrosis factor-related mediators
• Chemokines
• Growth factors
• Matrix metalloproteinases
• Extracellular matrix-modifying proteins
• Immune-modulating molecules

The exact composition of SASP varies according to cell type, senescence-inducing stimulus, duration, and tissue environment.

SASP can have beneficial functions. During wound healing, for example, senescent cells and their secreted factors can influence immune-cell recruitment and tissue remodeling.

However, chronic SASP production during aging can become harmful. Persistent inflammatory signaling can alter extracellular matrix structure, impair neighboring cells, promote fibrosis, and contribute to tissue dysfunction.

SASP can also influence cells that were not originally senescent. This phenomenon, sometimes referred to as paracrine senescence, may allow senescence-associated signals to spread through tissues.

6. Cellular Senescence and Aging

The relationship between senescence and aging is bidirectional.

Age-associated accumulation of molecular damage can promote cellular senescence, while senescent cells can contribute to age-related tissue dysfunction.

As individuals age, senescent cells can accumulate in several tissues. Their persistence may be promoted by declining immune surveillance and reduced efficiency of cellular clearance mechanisms.

Senescent cells can influence tissue function through SASP, altered extracellular matrix interactions, metabolic changes, and intercellular communication.

Thus, cellular senescence is increasingly regarded as a systemic component of biological aging rather than simply a localized cellular phenomenon.

7. Cellular Senescence in Age-Related Diseases

7.1 Cardiovascular Diseases

Cellular senescence contributes to vascular aging and cardiovascular dysfunction.

Senescent endothelial cells may exhibit impaired nitric oxide signaling, increased inflammatory activity, and reduced regenerative capacity.

Vascular smooth-muscle-cell senescence can influence vascular remodeling and atherosclerotic plaque development.

Cardiac fibroblast senescence may also contribute to extracellular matrix remodeling and fibrosis.

Through these mechanisms, senescence may contribute to hypertension, atherosclerosis, vascular stiffness, heart failure, and other cardiovascular conditions.

8. Cellular Senescence in Diabetes and Metabolic Disorders

Metabolic dysfunction and senescence are closely interconnected.

Obesity, hyperglycemia, insulin resistance, mitochondrial dysfunction, and chronic inflammation can promote senescence in adipose tissue and other metabolic organs.

Senescent adipocytes and stromal cells may release inflammatory SASP factors that interfere with normal metabolic signaling.

Cellular senescence has therefore been investigated as a possible contributor to obesity-associated inflammation, insulin resistance, type 2 diabetes, and metabolic syndrome.

9. Cellular Senescence and Neurodegenerative Diseases

The nervous system is particularly vulnerable to age-related cellular dysfunction.

Senescence-associated processes have been identified in several cell populations within the aging brain, including astrocytes, microglia, endothelial cells, and other supporting cells.

SASP-mediated inflammation may contribute to neuroinflammation and neuronal dysfunction.

Persistent DNA damage, mitochondrial dysfunction, oxidative stress, and impaired protein homeostasis may further promote senescence-associated changes.

These mechanisms have been investigated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The interaction between DNA damage, inflammation, and senescence is particularly important because chronic activation of these pathways can contribute to neurodegeneration.

10. Cellular Senescence and Osteoporosis

Bone remodeling requires a balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption.

Aging-associated accumulation of senescent cells can disrupt this balance through inflammatory signaling and altered cellular communication.

Senescent cells within bone and surrounding tissues may contribute to reduced bone formation, increased inflammatory activity, and impaired tissue regeneration.

These processes may contribute to age-related osteoporosis and skeletal fragility.

11. Cellular Senescence and Pulmonary Disease

Lung tissue is continuously exposed to environmental stressors, including air pollutants, cigarette smoke, and infectious agents.

Persistent oxidative stress and DNA damage can induce senescence in pulmonary epithelial cells and fibroblasts.

SASP-mediated inflammation and extracellular matrix remodeling can contribute to chronic pulmonary dysfunction.

Cellular senescence has consequently been investigated in chronic obstructive pulmonary disease, pulmonary fibrosis, and other age-associated respiratory disorders.

12. Cellular Senescence and Liver Disease

The liver has substantial regenerative capacity, but chronic metabolic stress, inflammation, oxidative injury, and toxic exposure can disrupt normal tissue repair.

Senescent hepatocytes and non-parenchymal cells may contribute to inflammatory signaling and fibrosis.

Cellular senescence has therefore been implicated in chronic liver disease and metabolic liver disorders.

The relationship is complex because senescence can initially limit proliferation of damaged cells while persistent senescent-cell accumulation may interfere with regeneration and promote pathological inflammation.

13. Cellular Senescence and Cancer

Senescence has a dual role in cancer biology.

On one hand, cellular senescence acts as a tumor-suppressive mechanism. A cell experiencing oncogenic activation or severe genomic damage may enter senescence instead of continuing uncontrolled proliferation.

On the other hand, persistent senescent cells can produce SASP factors that may promote inflammation, angiogenesis, tumor-cell invasion, and changes in the tumor microenvironment.

Consequently, the therapeutic significance of senescence in cancer depends on timing, tissue context, and the characteristics of the senescent population.

14. Biomarkers of Cellular Senescence

Identifying senescent cells in tissues remains a major scientific challenge.

Commonly investigated markers include:

• p16/CDKN2A
• p21/CDKN1A
• Senescence-associated β-galactosidase
• Persistent DNA damage foci
• γ-H2AX
• Lipofuscin accumulation
• Reduced Lamin B1
• SASP-related cytokines
• Changes in cell morphology
• Increased lysosomal activity

However, no single biomarker is universally specific for cellular senescence.

For example, p16 can be expressed in some non-senescent conditions, while DNA damage markers can also appear during transient cellular stress.

Consequently, researchers increasingly recommend combining multiple markers with functional and molecular characteristics when identifying senescent cells. The lack of universal biomarkers remains a major obstacle to translating senescence research into clinical applications.

Review Design

This article was developed as a narrative review focusing on the molecular mechanisms of cellular senescence and its relationship with aging and age-associated diseases.

Literature Search

Relevant scientific literature was identified using biomedical databases and peer-reviewed scientific journals.

Search terms included combinations of:

“cellular senescence,” “senescent cells,” “aging,” “cell cycle arrest,” “SASP,” “p16,” “p21,” “p53,” “DNA damage,” “telomere shortening,” “oxidative stress,” “mitochondrial dysfunction,” “senolytics,” “senomorphics,” “age-related diseases,” “cancer,” “diabetes,” “cardiovascular disease,” “neurodegeneration,” and “osteoporosis.”

Recent publications were prioritized, while foundational studies were incorporated where necessary to explain established concepts.

Inclusion Criteria

Studies were considered relevant when they:

1. Investigated molecular mechanisms of cellular senescence;
2. Examined senescence in aging;
3. Evaluated the relationship between senescence and human disease;
4. Investigated senescence biomarkers;
5. Examined senolytic or senomorphic interventions; or
6. Provided mechanistic evidence regarding senescence-associated signaling.

Exclusion Criteria

Publications without substantial relevance to cellular senescence, aging, molecular mechanisms, biomarkers, or therapeutic approaches were excluded from the main synthesis.

Data Synthesis

The available literature was organized into major themes covering senescence induction, molecular signaling, SASP, age-related diseases, biomarkers, and therapeutic interventions. Findings were synthesized qualitatively to identify established mechanisms and emerging therapeutic opportunities.

16. Results

The reviewed literature indicates that cellular senescence is a multifaceted biological process involving stable cell-cycle arrest together with substantial metabolic, structural, transcriptional, and secretory changes.

Several major observations emerged.

First, cellular senescence can be induced by diverse stressors, particularly persistent DNA damage, telomere dysfunction, oxidative stress, oncogene activation, and metabolic disturbances.

Second, the p53–p21 and p16–RB pathways represent major mechanisms responsible for establishing and maintaining cell-cycle arrest.

Third, senescent cells frequently develop SASP, which can influence inflammation, tissue remodeling, immune responses, and neighboring cells.

Fourth, accumulation of senescent cells has been associated with multiple age-related disorders, including metabolic, cardiovascular, pulmonary, neurological, skeletal, and hepatic diseases.

Fifth, emerging evidence supports therapeutic targeting of senescent cells. Senolytics, senomorphics, immune-mediated clearance, and pathway-specific interventions are being investigated in experimental models and early clinical research.

Finally, the lack of universally specific biomarkers and the heterogeneity of senescent cells remain major barriers to clinical translation.

17. Therapeutic Perspectives

Senolytic Therapy

Senolytics are agents designed to selectively eliminate senescent cells.

Senescent cells often become dependent on anti-apoptotic survival pathways. Senolytic compounds attempt to exploit these dependencies and induce apoptosis preferentially in senescent cells.

Experimental studies have demonstrated beneficial effects of senolytic strategies in several models of aging and chronic disease.

However, senescent cells can perform beneficial physiological functions, and broad elimination may therefore have unintended consequences.

Senomorphic Therapy

Senomorphic approaches do not necessarily eliminate senescent cells. Instead, they attempt to reduce harmful features such as SASP.

Potential targets include inflammatory signaling, NF-κB, mTOR, p38 MAPK, and other pathways controlling SASP production.

This approach may be particularly useful when senescent cells perform beneficial functions but their excessive inflammatory signaling is harmful.

Immune-Mediated Clearance

The immune system naturally participates in the removal of senescent cells.

Aging can impair immune surveillance, potentially allowing senescent cells to accumulate.

Therapeutic strategies that enhance immune recognition and clearance of senescent cells are therefore being investigated as potential senotherapeutic approaches.

Targeting DNA Damage

Because persistent DNA damage is an important driver of senescence, improving DNA repair and reducing genotoxic stress may provide another therapeutic strategy.

Approaches targeting genome stability, telomere maintenance, and DNA repair mechanisms are being explored as potential strategies for delaying senescence-associated pathology.

Mitochondrial and Metabolic Interventions

Mitochondrial dysfunction and metabolic alterations contribute to senescence development and maintenance.

Targeting mitochondrial oxidative stress, improving mitochondrial quality control, regulating nutrient-sensing pathways, and modulating cellular metabolism may therefore influence senescence.

The metabolic characteristics of senescent cells provide potential opportunities for therapeutic intervention.

Cellular senescence represents an important biological response that can be beneficial or harmful depending on the context.

Its protective role is particularly evident in tumor suppression. Preventing damaged cells from continuing to divide reduces the risk of malignant transformation. Senescence can also participate in normal developmental processes and tissue repair.

The problem arises when senescent cells persist and accumulate.

With aging, cellular damage increases while immune-mediated clearance and tissue regeneration may decline. This creates an environment in which senescent cells can persist for prolonged periods.

The SASP is central to this process. Persistent secretion of inflammatory mediators can influence neighboring cells, promote chronic inflammation, alter extracellular matrix organization, and impair tissue regeneration.

The connection between senescence and DNA damage is particularly important. Persistent DNA damage activates signaling pathways that maintain cell-cycle arrest and inflammatory responses. The interaction between DNA damage response and senescence may therefore represent a mechanistic link between molecular aging and age-associated disease.

Another important concept is that senescence is not a uniform state. Senescent cells differ according to their tissue of origin, initiating stress, metabolic environment, age, and duration of senescence.

This heterogeneity creates a major challenge for senotherapeutics. A drug that eliminates one senescent-cell population may have limited effects on another.

The identification of reliable biomarkers is therefore essential. Current markers such as p16, p21, β-galactosidase activity, DNA damage markers, and SASP components can provide useful information, but none is sufficient by itself to define all senescent cells.

Therapeutic research is consequently moving toward more precise approaches. Rather than attempting to eliminate all senescent cells, future strategies may selectively target specific senescent populations associated with particular diseases.

Clinical translation is progressing, particularly in metabolic disease, but significant questions remain regarding safety, treatment duration, patient selection, and long-term consequences.

19. Future Perspectives

Future research should focus on several priorities.

First, improved biomarkers are required to identify senescent cells accurately in human tissues.

Second, researchers need to establish how different senescent-cell populations contribute to specific diseases.

Third, clinical studies should determine whether senolytic or senomorphic interventions can produce meaningful improvements in human health rather than simply altering molecular biomarkers.

Fourth, combination therapies may become important. For example, elimination of senescent cells could potentially be combined with interventions that reduce inflammation or improve tissue regeneration.

Fifth, advances in single-cell sequencing, spatial transcriptomics, proteomics, metabolomics, and artificial intelligence may help identify senescent-cell subtypes and their tissue-specific functions.

The future of senescence research is therefore likely to move toward precision senotherapy, in which specific senescent populations are identified and selectively targeted according to disease context.

Cellular senescence is a fundamental biological process that protects organisms against uncontrolled proliferation and contributes to tissue development and repair. However, the persistent accumulation of senescent cells during aging can become detrimental.

The molecular mechanisms of senescence involve interconnected pathways including DNA damage response, telomere dysfunction, p53–p21 signaling, p16–RB activation, oxidative stress, mitochondrial dysfunction, metabolic reprogramming, epigenetic alterations, and inflammatory signaling.

Through SASP production and other forms of intercellular communication, senescent cells can influence surrounding tissues and contribute to chronic inflammation, fibrosis, impaired regeneration, and age-related functional decline.

Growing evidence links cellular senescence with cardiovascular disease, metabolic disorders, neurodegeneration, osteoporosis, pulmonary disease, liver disease, and cancer.

Senolytics, senomorphics, immune-based clearance, metabolic interventions, and approaches targeting DNA damage and mitochondrial dysfunction represent promising therapeutic directions. Nevertheless, the heterogeneity of senescent cells and the absence of universally specific biomarkers remain important challenges.

A better understanding of senescence at the molecular and tissue levels may ultimately enable targeted interventions that reduce age-related disease while preserving the beneficial physiological functions of senescence.

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Experimental Cell Research. 1961;25:585–621.
2. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–198.
3. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature Reviews Molecular Cell Biology. 2007;8:729–740.
4. Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813–827.
5. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–1217.
6. Wiley CD, Campisi J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nature Metabolism. 2021;3:1290–1301.
7. Gasek NS, Kuchel GA, Kirkland JL, Xu M. Strategies for targeting senescent cells in human disease. Nature Aging. 2021;1:870–879.
8. McHugh D, Durán I, Gil J. Senescence as a therapeutic target in cancer and age-related diseases. Nature Reviews Drug Discovery. 2025;24:57–71.
9. Wu Z, Qu J, Liu GH. Roles of chromatin and genome instability in cellular senescence and their relevance to ageing and related diseases. Nature Reviews Molecular Cell Biology. 2024;25:979–1000.
10. Chaib S, Palmer AK, Wyles SP, et al. Translating cellular senescence research into clinical practice for metabolic disease. Nature Reviews Endocrinology. 2026;22:102–115.
11. Ajoolabady A, Pratico D, Bahijri S, et al. Hallmarks of cellular senescence: biology, mechanisms, regulations. Experimental & Molecular Medicine. 2025;57:1482–1491.
12. Ajoolabady A, Pratico D, Bahijri S, et al. Hallmarks and mechanisms of cellular senescence in aging and disease. Cell Death Discovery. 2025;11:364.
13. Wiley CD, Velarde MC. Senescence and aging: cellular and molecular mechanisms. Current Opinion in Cell Biology. 2019;52:1–7.
14. Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nature Reviews Molecular Cell Biology. 2021;22:75–95.
15. Basisty N, Kale A, Jeon OH, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biology. 2020;18:e3000599.
16. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nature Medicine. 2015;21:1424–1435.
17. McHugh D, Gil J. Senescence and aging: causes, consequences, and therapeutic opportunities. Journal of Cell Biology. 2018;217:65–77.
18. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. Journal of Clinical Investigation. 2013;123:966–972.
19. Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21–28.
20. Yousefzadeh MJ, Zhao J, Bukata C, et al. Tissue specificity of senescent cell accumulation during physiologic and accelerated aging of mice. Aging Cell. 2020;19:e13094.
21. Zhang W, Song S, Zhang Y, et al. Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming. npj Aging. 2026;12:92.
22. Ovadya Y, Krizhanovsky V. Senescent cells: SASPected drivers of age-related pathologies. Biogerontology. 2018;19:465–473.
23. Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer and aging. Trends in Cell Biology. 2019;29:439–453.
24. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509:439–446.
25. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24:1246–1256.